Q3 2026 Biotech Events: Key Trials and FDA Decisions
By Priya Anand

The third quarter of 2026 is marked by critical clinical trials and regulatory decisions for several biotech companies, according to STAT's latest biotech scorecard. These events are expected to influence stock movements significantly.
Amylyx Pharmaceuticals is anticipated to release results from its Phase 3 LUCIDITY trial for avexitide, targeting post-bariatric hypoglycemia, a rare metabolic disorder. The specific date for these results remains unspecified beyond the third quarter.
Biogen is set to present detailed mid-stage results for its Alzheimer's candidate, diranersen, which targets the tau protein. This presentation is scheduled for July 14 at the Alzheimer's Association International Conference.
Additionally, several FDA PDUFA decision dates are slated for early to mid-July. These include Insmed's brensocatib for bronchiectasis on July 2, Mirum's volixibat for progressive familial intrahepatic cholestasis on July 7, Acadia's trofinetide for adult Rett syndrome expansion on July 14, Ultragenyx's UX111 gene therapy for MPS IIIA on July 20, and Travere's sparsentan for FSGS expansion on July 24.
These events reflect a broader trend of concentrated biotech regulatory activity this quarter, as highlighted by both STAT and the ClinicalInvestor calendar.